dapagliflozin
- RxCUI
- 1488564
- RxNorm name
- dapagliflozin
- Term type
- IN
- Status
- Active
- Updated
- 2026-08-12 12:31:09
RxNorm Status History#
- Status
- Active
- Source
- RXNORM
- Current
- YES
- Release start
- 032014
- Active start
- 032014
- Multiple ingredient
- NO
- Branded
- NO
Source Vocabulary Codes#
UNII Substances#
No records found.
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| Dapagliflozin | DAPAGLIFLOZIN | Apotex Corp. | bd9766c5-104f-4636-897d-b6c92eb94f18 | 2026-04-10 | Warnings, Adverse reactions | DAPAGLIFLOZIN |
| Dapagliflozin | DAPAGLIFLOZIN | Zydus Lifesciences Limited | db668c5c-2d49-41c8-8ffd-c2b2652b621a | 2026-04-06 | DAPAGLIFLOZIN | |
| DAPAGLIFLOZIN | DAPAGLIFLOZIN | Bryant Ranch Prepack | 979205ee-b0b8-4483-ae61-f283f750bb7f | 2024-08-08 | Warnings, Adverse reactions | DAPAGLIFLOZIN |
| DAPAGLIFLOZIN | DAPAGLIFLOZIN | A-S Medication Solutions | 82cdd5ad-df2b-4bdd-a3a6-a059040100b4 | 2024-06-28 | Warnings, Adverse reactions | DAPAGLIFLOZIN |
| DAPAGLIFLOZIN | DAPAGLIFLOZIN | A-S Medication Solutions | 87521963-0d2a-4a2a-89c6-d50e8582419e | 2024-06-28 | Warnings, Adverse reactions | DAPAGLIFLOZIN |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.
DailyMed RxNorm Mappings#
No records found.
Drug Classes#
| Source | Class ID | Class | Type | Relationship | Drug concept |
|---|---|---|---|---|---|
| ATC | A10BD | Combinations of oral blood glucose lowering drugs | ATC1-4 | dapagliflozin / metformin | |
| ATC | A10BD | Combinations of oral blood glucose lowering drugs | ATC1-4 | dapagliflozin / metformin / saxagliptin | |
| ATC | A10BD | Combinations of oral blood glucose lowering drugs | ATC1-4 | dapagliflozin / saxagliptin | |
| ATC | A10BK | Sodium-glucose co-transporter 2 (SGLT2) inhibitors | ATC1-4 | dapagliflozin | |
| FDASPL | N0000187059 | Sodium-Glucose Cotransporter 2 Inhibitor | EPC | has_epc | dapagliflozin |
| FDASPL | N0000187058 | Sodium-Glucose Transporter 2 Inhibitors | MOA | has_moa | dapagliflozin |
| MEDRT | D001559 | Benzhydryl Compounds | CHEM | has_ingredient | dapagliflozin |
| MEDRT | D005960 | Glucosides | CHEM | has_ingredient | dapagliflozin |
| MEDRT | D003924 | Diabetes Mellitus, Type 2 | DISEASE | may_treat | dapagliflozin propanediol |
| MEDRT | D003924 | Diabetes Mellitus, Type 2 | DISEASE | may_treat | dapagliflozin 2,3-butanediol monohydrate |
| MEDRT | D003924 | Diabetes Mellitus, Type 2 | DISEASE | may_treat | dapagliflozin |
| MEDRT | D004342 | Drug Hypersensitivity | DISEASE | ci_with | dapagliflozin propanediol |
| MEDRT | D006333 | Heart Failure | DISEASE | may_treat | dapagliflozin 2,3-butanediol monohydrate |
| MEDRT | D006333 | Heart Failure | DISEASE | may_treat | dapagliflozin |
| MEDRT | D051437 | Renal Insufficiency | DISEASE | ci_with | dapagliflozin propanediol |
| MEDRT | N0000187058 | Sodium-Glucose Transporter 2 Inhibitors | MOA | has_moa | dapagliflozin 2,3-butanediol monohydrate |
| MEDRT | N0000187058 | Sodium-Glucose Transporter 2 Inhibitors | MOA | has_moa | dapagliflozin |
| MEDRT | N0000187058 | Sodium-Glucose Transporter 2 Inhibitors | MOA | has_moa | dapagliflozin propanediol |
| MEDRT | N0000175650 | Decreased Sympathetic Activity | PE | has_pe | dapagliflozin |
| MEDRT | N0000175650 | Decreased Sympathetic Activity | PE | has_pe | dapagliflozin 2,3-butanediol monohydrate |
| MEDRT | N0000009556 | Increased Renal Organic Ion Excretion | PE | has_pe | dapagliflozin |
| MEDRT | N0000009556 | Increased Renal Organic Ion Excretion | PE | has_pe | dapagliflozin 2,3-butanediol monohydrate |
| MEDRT | N0000009556 | Increased Renal Organic Ion Excretion | PE | has_pe | dapagliflozin propanediol |
| MEDRT | N0000009830 | Renal Ion Transport Alteration | PE | has_pe | dapagliflozin |
| MEDRT | N0000009830 | Renal Ion Transport Alteration | PE | has_pe | dapagliflozin propanediol |
| MEDRT | N0000009830 | Renal Ion Transport Alteration | PE | has_pe | dapagliflozin 2,3-butanediol monohydrate |
Properties#
| Category | Property | Value |
|---|---|---|
| ATTRIBUTES | GENERAL_CARDINALITY | SINGLE |
| ATTRIBUTES | RXNAV_HUMAN_DRUG | US |
| CODES | ATC | A10BK01 |
| CODES | DRUGBANK | DB06292 |
| CODES | SNOMEDCT | 703674001 |
| CODES | SNOMEDCT | 703678003 |
| CODES | USP | m17996 |
| CODES | VUID | 4033035 |
| SOURCES | Source | Anatomical Therapeutic Chemical |
| SOURCES | Source | Drug Bank |
| SOURCES | Source | Gold Standard Alchemy |
| SOURCES | Source | Metathesaurus FDA Structured Product Labels |
| SOURCES | Source | Multum MediSource Lexicon |
| SOURCES | Source | National Drug Data File Plus Source Vocabulary |
| SOURCES | Source | United States Pharmacopeia |
| SOURCES | Source | US Edition of SNOMED_CT |
| SOURCES | Source | Veterans Health Administration National Drug File |